Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1634 1682 1683 1699 1758
This examiner grants 46% of resolved cases
Examiner STEPHEN THOMAS KAPUSHOC is part of Tech Center 1700 and Art Unit 1634. The examiner has 739 resolved cases, which is a substantial number that provides a clear picture of prosecution trends. This 739 case history indicates a well-established practice within the art unit.
The allowance rate is 46.5 percent. This 46.5 percent rate is paired with a significant interview lift of 53.5 percent. The 53.5 percent lift suggests that applications are much more likely to be allowed if an interview is conducted compared to the 46.5 percent baseline. For practitioners in Art Unit 1634, the 53.5 percent lift is one of the most important metrics for determining prosecution strategy.
The median days to allowance is 1378. This 1378 day duration represents the typical timeline for applications that result in a grant. The 46.5 percent allowance rate and the 1378 day median suggest that prosecution can be both lengthy and rigorous. However, the 53.5 percent interview lift offers a clear path for improving outcomes in Tech Center 1700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18340581 | COMPOSITIONS AND METHODS FOR HIGHLY SENSITIVE DETECTION OF TARGET SEQUENCES IN MULTIPLEX REACTIONS | Non-Final OA | Life Technologies Corporation |
| 18568042 | INTERNAL STANDARD NUCLEIC ACID FOR QUANTIFYING EUKARYOTIC MICROORGANISMS | Non-Final OA | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY |
| 17926804 | EPIGENETIC MODIFICATION OF SELECT GENES AS MARKERS OF HYPERSOMNOLENCE | Final Rejection | Wisconsin Alumni Research Foundation |
| 17776822 | METHODS OF SYNTHESIZING RNA MOLECULES | Final Rejection | BAYER HEALTHCARE LLC |
| 18291403 | PCR KIT-OF-PARTS, METHOD AND SYSTEM | Non-Final OA | Hewlett-Packard Development Company, L.P. |
| 17999137 | PERSONALISED RECOMMENDED DAILY INTAKE FOR NUTRIENTS BASED ON INDIVIDUAL GENETIC RISK SCORES | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18168955 | METHODS OF DETERMINING COVID-19 MORTALITY RISK | Non-Final OA | WASHINGTON UNIVERSITY |
| 18034876 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | Non-Final OA | Massachusetts Institute of Technology |
| 18435731 | NUCLEIC ACID SEQUENCE ANALYSIS | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18426589 | GENE ANALYSIS METHOD AND KIT FOR GENE ANALYSIS | Non-Final OA | HITACHI, LTD. |
| 18510752 | CONNECTOR, CONNECTOR-LABEL CONJUGATE AND MARKER FOR ANALYSING BIOLOGICAL SAMPLES | Non-Final OA | LEICA MICROSYSTEMS CMS GMBH |
| 17372113 | COMPOSITIONS AND METHODS RELATED TO DIFFERENTIALLY METHYLATED DNA SEQUENCES ASSOCIATED WITH MONOALLELIC GENE EXPRESSION AND DISEASE | Final Rejection | North Carolina State University |
| 18258872 | METHODS FOR PERFORMING MULTIPLEXED REAL-TIME PCR WITH THE USE OF LARGE STOKES SHIFT FLUORESCENT DYES | Non-Final OA | Roche Molecular Systems, Inc. |
| 18270684 | HIGH-SPATIAL-RESOLUTION EPIGENOMIC PROFILING | Non-Final OA | YALE UNIVERSITY |
| 18681271 | COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS | Non-Final OA | The University of Hong Kong |
| 18403902 | MULTI-OMIC ANALYSIS IN MONODISPERSE DROPLETS | Non-Final OA | ILLUMINA, INC. |
| 18300477 | Molecular Biomarkers for Predicting Patient Response to Steroid Therapy | Final Rejection | Florida State University Research Foundation, Inc. |
| 18258485 | IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 17787433 | NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | Non-Final OA | MedImmune Limited |
| 18572107 | UNIT-DNA COMPOSITION FOR SPATIAL BARCODING AND SEQUENCING | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18516241 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | Non-Final OA | MAGI EUREGIO SCS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy